Lantheus Holdings Inc (LNTH) was Resumed by Credit Suisse to “Neutral”. Credit Suisse advised their investors in a research report released on Sep 23, 2016.
Lantheus Holdings Inc opened for trading at $8.78 and hit $9.13 on the upside on Thursday, eventually ending the session at $9.07, with a gain of 4.86% or 0.42 points. The heightened volatility saw the trading volume jump to 5,24,844 shares. Company has a market cap of $276 M.
Lantheus Holdings Inc. is engaged in developing manufacturing selling and distributing diagnostic medical imaging agents and products that assist clinicians in the diagnosis of cardiovascular and other diseases. The Company’s medical imaging agents are used to diagnose coronary artery disease congestive heart failure stroke peripheral vascular disease and other diseases. The Company’s products include contrast agents and medical radiopharmaceuticals including technetium generators. The Company’s products include DEFINITY TechneLite Xenon Xe 133 Gas Cardiolite Neurolite Thallium Tl 201 Gallium Ga 67 Gludef Quadramet and Ablavar. The Company is also engaged in developing agents such as Flurpiridaz F 18 which is a myocardial perfusion imaging agent; 18F LMI 1195 which is a cardiac neuronal imaging agent and LMI 1174 which is a vascular remodeling imaging agent.